SCHEMBL30450186

SCHEMBL30450186

CN1CCCc2cc(N3CCC(=O)NC3=O)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 10/20 0.50
DDB1 Q16531 9/20 0.50
ALDH1A1 P00352 4/20 0.49
HPGD P15428 3/20 0.49
GAA P10253 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39
PRKAG2 Q9UGJ0 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
TP53 P04637 1/20 0.38
KDM4E B2RXH2 2/20 0.38
GLA P06280 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26684049 1.00 CRBN (0.50) CRBNDDB1ALDH1A1HPGDGAA
SCHEMBL26684176 0.92 CRBN (0.56) CRBNDDB1ALDH1A1HPGDGAA
SCHEMBL30449971 0.89 CRBN (0.50) CRBNDDB1ALDH1A1HPGDGAA
SCHEMBL26684064 0.89 CRBN (0.50) CRBNDDB1ALDH1A1HPGDGAA
SCHEMBL26683782 0.81 CRBN (0.56) CRBNDDB1ALDH1A1HPGDKDM4E
SCHEMBL25338831 0.81 CRBN (0.48) CRBNDDB1ALDH1A1HPGDKDM4E
SCHEMBL26844954 0.77 BRD4 (0.49) CRBNDDB1KDM4EHSD17B10
SCHEMBL26683933 0.76 CRBN (0.54) CRBNDDB1ALDH1A1HPGDKDM4E
SCHEMBL30449361 0.76 CRBN (0.54) CRBNDDB1ALDH1A1HPGDKDM4E
SCHEMBL30449374 0.75 CRBN (0.53) CRBNDDB1ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
CN-116249554-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2023-06-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER RARA, RARG, RARB CRBN 2312/4885DDB1 4162/4885ALDH1A1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.